company background image
29A logo

Amphastar Pharmaceuticals DB:29A Stock Report

Last Price

€37.46

Market Cap

€1.8b

7D

-8.0%

1Y

-30.6%

Updated

23 Dec, 2024

Data

Company Financials +

Amphastar Pharmaceuticals, Inc.

DB:29A Stock Report

Market Cap: €1.8b

29A Stock Overview

A bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More details

29A fundamental analysis
Snowflake Score
Valuation6/6
Future Growth3/6
Past Performance3/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Amphastar Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Amphastar Pharmaceuticals
Historical stock prices
Current Share PriceUS$37.46
52 Week HighUS$58.50
52 Week LowUS$34.10
Beta0.79
1 Month Change-13.73%
3 Month Change-13.33%
1 Year Change-30.63%
3 Year Change89.19%
5 Year Change120.35%
Change since IPO256.69%

Recent News & Updates

Recent updates

Shareholder Returns

29ADE PharmaceuticalsDE Market
7D-8.0%-2.2%-2.0%
1Y-30.6%-15.6%6.9%

Return vs Industry: 29A underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: 29A underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is 29A's price volatile compared to industry and market?
29A volatility
29A Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 29A has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 29A's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19961,761Jack Zhangwww.amphastar.com

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures.

Amphastar Pharmaceuticals, Inc. Fundamentals Summary

How do Amphastar Pharmaceuticals's earnings and revenue compare to its market cap?
29A fundamental statistics
Market cap€1.80b
Earnings (TTM)€151.16m
Revenue (TTM)€693.45m

11.9x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
29A income statement (TTM)
RevenueUS$723.55m
Cost of RevenueUS$340.20m
Gross ProfitUS$383.35m
Other ExpensesUS$225.63m
EarningsUS$157.72m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)3.28
Gross Margin52.98%
Net Profit Margin21.80%
Debt/Equity Ratio81.9%

How did 29A perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 17:08
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amphastar Pharmaceuticals, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
Jason Matthew GerberryBofA Global Research
Timothy ChiangCapital One Securities, Inc.